학술논문

1506TiPPhase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC.
Document Type
Article
Source
Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Subject
*EPIDERMAL growth factor receptors
*NON-small-cell lung carcinoma
Language
ISSN
0923-7534